TV Interview CEO Bob Proulx Explains Cancer Diagnostic https://youtu.be/X4HLKyIl6Zo

Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)

Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.

About Manhattan Scientifics Inc.

Manhattan Scientifics is focused on the commercialization of disruptive technologies

Forward-looking statement:

This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.

Marvin Maslow, Chairman: 917.923.3300 Manny Tsoupanarias, CEO : 917.688.4158

Imagion Biosystems (ASX:IBX)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Imagion Biosystems Charts.
Imagion Biosystems (ASX:IBX)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Imagion Biosystems Charts.